Key clinical point: A high dose of teriparatide plus denosumab can greatly increase bone mineral density in postmenopausal women with osteoporosis.

Major finding: Patients receiving 40 μg of teriparatide had a significantly higher increase in mean lumbar spine aBMD (17.5%), compared with those receiving the standard dose of 20 μg (9.5%; 95% CI, 5.5-10.6; P < .0001.

Study details: An open-label, controlled, randomized trial of 76 postmenopausal women with osteoporosis.

Disclosures: The study was supported by the Dart Family Foundation, the National Institutes of Health, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases. Eli Lilly and Amgen supplied the drugs for the study. The authors reported numerous conflicts of interest, including receiving grants, reimbursements, and personal fees from various pharmaceutical companies, committees, and research institutes.